Abbott Introduces Lab-based Blood Test to Help Evaluate Concussion

• Abbott’s lab-based mild traumatic brain injury (mTBI) test can help provide reliable results in 18 minutes enabling doctors to evaluate patients with mild traumatic brain injury (mTBI), commonly known as concussion, within 12 hours of a head injury
• Test has the potential to eliminate the need for a CT scan by up to 40%, helping in reducing the time spent in emergency care 

MUMBAI, India : Abbott, the global healthcare company, announced the launch of its laboratory-based blood test to evaluate mild traumatic brain injury (mTBI), commonly known as concussions. The traumatic brain injury (TBI) test runs on Abbott’s Alinity i and Architect i1000SR laboratory instruments, which are available in major hospitals and laboratories such as Apollo, Hyderabad and Neuberg Supratech Laboratory.

The test offers a reliable result in 18 minutes to help clinicians quickly evaluate brain injury and triage mTBI patients. The diagnostic tool also helps eliminate the need for CT scans by up to 40% with a high degree of certainty eliminating wait time at the hospital and unnecessary exposure to radiation. The test measures two biomarkers in the blood – ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) – that, in elevated concentrations, are correlated to brain injury.

The test can help streamline care benefiting both patients and the healthcare system. This is particularly important in areas where access to CT systems may be limited. 

Ravi Sinha, General Manager & Country Head – Diagnostics, Abbott India said, “Abbott’s TBI blood test improves patient evaluation and delivers reliable results in just minutes helping doctors quickly and accurately rule out the need for a CT scan. This means less time spent in emergency care and less stress for patients and families. The test enables early and accurate evaluation to ensure better long-term health outcomes.”